



# Macrophagic Activation Syndrome Revealing Tuberculosis: A Case Report

**R. Majd <sup>a\*</sup>, A. Radi <sup>a</sup>, A. Laarej <sup>a</sup>, A. Hassani <sup>a</sup>  
and R. Abilkassem <sup>a</sup>**

<sup>a</sup> *Department of Paediatrics, Hôpital Militaire Mohamed V Rabat, Morocco.*

## **Authors' contributions**

*This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.*

## **Article Information**

DOI: 10.9734/AJPR/2024/v14i6349

## **Open Peer Review History:**

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/115830>

**Case Report**

**Received: 19/02/2024**  
**Accepted: 23/04/2024**  
**Published: 01/05/2024**

## **ABSTRACT**

We present a case involving an immunocompetent infant diagnosed with miliary tuberculosis complicated by macrophage activation syndrome. Macrophage activation syndrome (MAS), also known as bone marrow hemophagocytosis, presents as a non-specific clinical condition characterized by fever and hepatosplenomegaly. A 22-month-old infant from a non-consanguineous marriage, the only child in the family, was admitted to a regional hospital due to prolonged fever lasting 15 days. The syndrome can manifest as a primary disorder (familial HLH) due to various genetic mutations or as a sporadic secondary disorder triggered by infections, autoimmune diseases, or malignant conditions. The early initiation of antibacillary treatment in AMS complicating tuberculosis without the use of immunosuppressive drugs provides better management and improves the vital prognosis.

**Keywords:** *Hemophagocytosis; antibacillary treatment; immunosuppressive drugs; macrophage activation syndrome.*

\*Corresponding author: Email: [majd.rajaa9@gmail.com](mailto:majd.rajaa9@gmail.com), [m.rajaa9@gmail.com](mailto:m.rajaa9@gmail.com);

## 1. INTRODUCTION

Macrophage activation syndrome (MAS), also known as bone marrow hemophagocytosis, presents as a non-specific clinical condition characterized by fever and hepatosplenomegaly. Common laboratory findings include pancytopenia, hypertriglyceridemia, and hyperferritinemia. Despite its rarity, MAS has been reported in association with tuberculosis. Here, we present a case involving an immunocompetent infant diagnosed with miliary tuberculosis complicated by macrophage activation syndrome.

## 2. CASE PRESENTATION

A 22-month-old infant from a non-consanguineous marriage, the only child in the family, was admitted to a regional hospital due to prolonged fever lasting 15 days. There was no history of tuberculosis contagion, but the infant had a history of consuming unpasteurized milk. The fever was accompanied by anorexia and weight loss.

Initial investigations revealed normal results from cerebrospinal fluid and urine tests, sterile blood cultures, anemia with hemoglobin levels of 8g/l, and a C-reactive protein (CRP) level of 200 mg/l. Treatment with a third-generation cephalosporin was initiated and continued for 7 days without improvement. The fever persisted, and the infant's general condition worsened.

On day 21 of fever, the patient was transferred to a level 3 hospital. Upon admission, the infant appeared conscious but pale, with a skin rash corresponding to the fever peak. The infant was hypotonic, experiencing polypnea and tachycardia, and was irritable. The body temperature was recorded at 38°C, with no presence of purpuric spots or jaundice. The patient was hemodynamically stable but exhibited hepatomegaly, with a liver span of 12 cm.


The paraclinical work-up revealed hypofibrinogenemia (1.4 g/l), hyperferritinemia (926 ng/ml), hypertriglyceridemia (2.70 g/l, reference range: 0.6-1.50), hypoproteinemia (48 g/l), and anemia (8 g/dl). Both the tuberculin skin test (TST) and gastric tube test for BK were negative, while Quantiferon testing returned positive results.

Chest X-ray findings displayed an interstitial syndrome consistent with a tubercular miliary appearance (see Fig. 1), while thoraco-abdominal CT scan results exhibited bilateral micronodular infiltration of symmetrical and homogeneous distribution throughout the parenchyma, indicative of an interstitial syndrome. No mediastinal adenopathy was observed, and homogeneous hepatomegaly was noted (see Fig. 2).


Additionally, the medullogram revealed evidence of haemophagocytosis (see Fig. 3). The patient was commenced on anti-bacillary treatment, resulting in a favorable outcome.



**Fig. 1. Chest X-ray demonstrating a tubercular miliary pattern**



**Fig. 2. Bilateral micronodular infiltration symmetrically and homogeneously distributed throughout the parenchyma, resulting in an interstitial syndrome. No mediastinal adenopathy is evident (A). Figure 2B: Homogeneous hepatosplenomegaly**



**Fig. 3. Presence of numerous images showing haemophagocytosis**

### 3. DISCUSSION

Macrophage activation syndrome (MAS), also known as hemophagocytic lymphohistiocytosis (HLH), was initially described by Scott and Robb-Smith in 1939. It is characterized by an inadequate immune response, marked by the proliferation and activation of macrophages, leading to excessive phagocytosis of hematological precursors such as erythrocytes, platelets, etc. This syndrome can manifest as a primary disorder (familial HLH) due to various genetic mutations or as a sporadic secondary disorder triggered by infections, autoimmune diseases, or malignant conditions [1].

According to the histocytes society protocol entitled HLH 2004 [2], the diagnosis of HLH can be established if five of the following eight diagnostic criteria are met (i) fever (27 days), (ii) splenomegaly, (iii) cytopenia ( $\geq 2$  lines) anaemia (haemoglobin  $<9.0$  g/dL), thrombocytopenia ( $<100,000$  cells) and neutropenia (ANC  $<1,000$ ), (iv) hypertriglyceridaemia ( $\geq 265$  mg/dL) and/or hypofibrinogenaemia ( $<1.5$  g/L), (v) haemophagocytosis (bone marrow, spleen, lymph node), (vi) low/absent NK cell activity, (vii) hyperferritinaemia (2500 mcg/L) and (viii) increase in soluble CD25  $>2400$  units/mL. In our case, six out of eight criteria were present.

Joshua Osawicki et al conducted “a search of the English-language literature and identified 13 other cases of tuberculosis complicated by HLH in children or adolescents. The age of the patients at presentation ranged from 2 weeks to 17 years. With the inclusion of the current case, there were 8 patients aged 2 months or less. Three patients died, despite immunomodulatory therapy combined with anti-tuberculosis treatment in two”. “In 1 fatal case, which occurred in a non-endemic setting (USA) and despite a thorough investigation, the diagnosis of tuberculosis remained unknown until an autopsy was performed. Of 11 surviving patients, 3 received treatment only antituberculosis and 8 received both antituberculosis and immunotherapies (4 had corticosteroids, 5 had intravenous immunotherapy, 1 cyclosporine and 1 etoposide). In 10 out of 14 cases, there was evidence of disseminated TB, including in 6 of the patients aged 2 months or less, with pulmonary disease in the remaining 4 cases. All patients had fever, 13 of 14 had organomegaly and 13 of 14 had thrombocytopenia and/or pancytopenia” [3].

Often, in the literature, when tuberculosis is associated with macrophagic activation syndrome, the two elements are diagnosed simultaneously. In addition, the diagnosis of tuberculosis may be identified late in the course of the diagnosis of MAS [4].

Thanks to PCR, the diagnosis of tuberculosis was detected in 70% of cases, whereas culture was only able to detect tuberculosis in 3.3% of cases [5].

#### 4. CONCLUSION

Macrophagic activation syndrome is a serious, often unrecognised, life-threatening condition which can complicate various infectious diseases. [6].tuberculosis, the early initiation of antibacillary treatment in AMS complicating tuberculosis without the use of immunosuppressive drugs provides better management and improves the vital prognosis.

#### CONSENT

As per international standard, parental written consent has been collected and preserved by the author(s).

#### ETHICAL APPROVAL

It is not applicable.

#### COMPETING INTERESTS

Authors have declared that no competing interests exist.

#### RÉFÉRENCES

1. Filipovich AH, Chandrakasan S. Pathogenèse de la lymphohistiocytose hémophagocytaire. *Hematol Oncol Clin North Am.* 2015;29:895-902. DOI:10.1016/j.hoc.2015.06.007
2. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer.* 2007;48:124-131.
3. Joshua Osawicki, MBBS, Shiqi Wang, MBBS, § et al. Tuberculose Congénitale Compliquée Par LA Lymphohistiocytose Hémophagocytaire Copyright © 2015 Wolters Kluwer Health
4. Ju-Hee Seo, MD, Jun Ah Lee, MD, Dong Ho Kim, MD, Joongbum Cho, MD\*, Jung Sub Lim, MD, PhD Hémophagocytose associée à la tuberculose chez un adolescent diagnostiquée par réaction en chaîne de la polymérase *Korean J Pediatr.* 2016;59 (1):43-46
5. Dilber E, Erduran E, Kalyoncu M, Aynaci FM, Okten A, Ahmetoglu A. Hemophagocytic syndrome as an initial presentation of miliary tuberculosis without pulmonary findings. *Scand J Infect Dis* 2002;34:689-92.
6. Gonzalez F, Vincent F. Cohen Infection-related hemophagocytic syndrome: Aetiologies and management *Réanimation (200 Réanimation.* 2009;18:284—290:18, 284—290.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:  
<https://www.sdiarticle5.com/review-history/115830>